Skip to content
Peptigraph home

CJC-1295 + Ipamorelin and BPC-157 Together: What Is Known

CJC-1295 + Ipamorelin and BPC-157 taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH + GHRP blendNot FDA approved · research blendCJC-1295 + IpamorelinUnapproved blend of CJC-1295 (no DAC) and ipamorelin; an FDA Drugs@FDA search for the CJC-1295 component returned no matches, so no approved product was found.[14]Growth hormoneGastric pentadecapeptidePCAC voted 8–6 for 503A (Jul 2026)BPC-157BPC-157, an experimental gastric pentadecapeptide, not an approved drug; human evidence is a few small uncontrolled reports, including complete symptom resolution in 10 of 12 patients in a bladder pilot.[11]Healing & recovery
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 7 results, 2 Oct 2026).

Neither is FDA approved for use in people, and we have no sourced data on combining them.
Each component

Side by side

Showing 12 of 12 fields where the two differ.

FieldCJC-1295 + IpamorelinBPC-157
ClassGHRH + GHRP blendGastric pentadecapeptide
Also calledCJC/IpaBPC, body protection compound, Pentadecapeptide BPC 157
CategoryGrowth hormoneHealing & recovery
FDA statusNot FDA approved · research blendPCAC voted 8–6 for 503A (Jul 2026)
PCAC vote, Jul 2026Not on the Jul 2026 agendaPCAC voted 8–6 for the 503A list (Jul 2026); not finalized
WADAProhibited by WADA (S2.2.4)Both components are named in S2.2.4 (CJC-1295 as a GHRH analogue, ipamorelin as a secretagogue), so the blend is prohibited at all times.Prohibited by WADA (S0)BPC-157 is named in S0 (non-approved substances), prohibited at all times, in and out of competition.
Anti-doping detection
  • After nasal dosing, ipamorelin metabolites were still found in urine after the parent drug was gone (samples were collected for 2 days).PMID 25869809
  • A 2023 method detects BPC-157 and five main metabolites in human urine at very low concentrations.PMID 37959764
  • A 2017 anti-doping lab method detects BPC 157 in urine; the peptide was stable in urine for at least 4 days.PMID 28035768
Half-lifeIpamorelin: 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717
Evidence strengthHuman RCT evidence, 4 of 4Ipamorelin: International journal of colorectal disease 2014, PMID 25331030Human observational evidence, 3 of 4Strongest: Alternative therapies in health and medicine 2025, PMID 40131143
Human studies we summarised6 human (3 randomized or controlled) of 19 summarised, across ingredients3 human (0 randomized or controlled) of 25 summarised
Typical study doses
Vial sizes sold10 mg2 mg, 5 mg, 10 mg, 20 mg

The blend and its status

A Drugs@FDA lookup for the CJC-1295/ipamorelin blend returned no match.[14]

After multiple CJC-1295 doses in the cited trial, mean IGF-I levels stayed above baseline for up to 28 d.[6]

BPC-157 evidence

In transected rat Achilles tendon, BPC 157 improved biomechanical and functional recovery; this is rat data.[16]

The sports-medicine review of BPC-157 states that no clinical safety data were found.[17]

CJC-1295 safety record

In the CJC-1295 dose-escalation trials, no serious adverse reactions were reported.[6]

Which CJC-1295 do the human data cover?

A review of performance peptides lists CJC-1295 with a Drug Affinity Complex (DAC) and CJC-1295 without DAC as separate agents.[18]

Tested together?

The search for the blend with BPC-157 returned 7 PubMed records, none classed as a study of the combination.

Calculated from pubmed query ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])); search date 2026-10-02; records returned 7; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key bpc-157__cjc-1295-ipamorelin); no arithmetic applied.

Common questions

Can you stack CJC-1295/ipamorelin with BPC-157?

No study tested that three-peptide combination; the sources only cover the pieces separately.[6]

Sources

  1. 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
  4. 4Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  5. 5Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  6. 6Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  7. 7Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
  8. 8Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
  9. 9Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
  10. 10Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
  11. 11Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.Alternative therapies in health and medicine · 2024PMID 39325560Accessed 2 Oct 2026
  12. 12Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
  13. 13PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab]))PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  15. 15Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
  16. 16Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2003PMID 14554208Accessed 2 Oct 2026
  17. 17Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025PMID 40756949Accessed 2 Oct 2026
  18. 18The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026

Found an error? Report a correction.